Researchers and doctors are willing to diagnose the target of viral pathogens, but it is extremely puzzled for them to only depend on clinical symptoms and epidemiology to detect the real one. With the high developed in vitro diagnose (IVD) systems and they have become mainly branches of the virology research field. IVDs play key roles in both viral disease prevention and control, largely because of the lack of effective drug treatments. There are three main methods, including the virus isolations, the immunological methods and the molecular assays, to diagnose the virus pathogens. And the latter two ways are more usual and convenient in current clinical tests, like ELISAs and nucleic acid tests [1] .
For the development of viral pathogens in vitro diagnostic reagents, the reference materials play important roles for the test data accuracy and product quality NAT assays can fulfill all requirements of the government institutes, including analytical sensitivity, analytical specificity, reproducibility/precision, while guarantee a reliable and highly sensitive detection of HIV-1, HCV, HBV, and HAV in cadaveric serum and plasma samples in cadaveric tissue transplants [2] .
FDA has been involved in the regulation of in vitro diagnostic devices (IVDs or laboratory tests) since the introduction of the Medical Device Amendments of 1976 [3] . For years, genetic tests are received and reviewed by the FDA in the same manner as other in vitro diagnostic tests [4] .
Facts tell us that the nucleic acid testing has taken significant parts in clinic diagnosis markets. Lots of pharmaceutical enterprises
give one-step service to the hospitals for the infective disease diagnosing and the safety of tissues for transplantation by using NAT in HAV， HBV， HCV and HIV et al. Failure of the rapid kits to detect HIV, HBV and HCV reactive samples may be due to 1) Inadequate coating of the antigens, 2) Nature of the antigens used and 3) Genetic heterogeneity of the virus. Therefore, the shows that the rapid tests are inferior compared to ELISA. And they have not been recommended for screening blood donors [5] .
1.3 Comparison of ELISA and rapid screening tests As mentioned before, NAT systems significantly shorten the diagnostic window period, because the viral genome appears much earlier than antigens or antibodies by using immunoassays in the infection cycle [2] . However, most of the rapid assays detect recombinant proteins from the prototype virus alone, specifically for HCV [2] . Variants of HCV may differ substant--ially in nucleotide sequence from one to another and show varied geographical and epidemiological distributions. For years, the efficiency and reliable are two rubs in the IVD markets and tissue transplant platforms. Admittedly, every coin has two side, we cannot court the better technology for further infective diagnose. Well, I rather prefer the view that all the IVDs tests, both NATs and protein interaction methods, will come together to create a higher and safer clinic environments.
Reference materials use in IVDs 2.1 Characters of biological reference materials
Chemically synthesized drugs are less complicated than biological medicines, as they cannot be well-defined and controlled by using standard physiochemical means alone. However, a biological reference material plays a key role to ensure standardization by using bioassays. And the "gold standard", provided by WHO biological reference materials centers, is considered the International Standards around the world. In these fields, NIBSC is responsible for more than 90% of WHO
International
Standards, including development, production and distribu--tion. Over 800 biological reference materials are listed in its catalogue [6] .
The traceability of values assigned to calibrators and control materials must be assured through available reference measurement procedures and/or available reference materials of 'a higher order', emphasized by the European Directive 98/79/EC on in vitro diagnostic medical devices, which has some vital requirements for a diagnostic test to be placed on the market. Representatives from Competent Regulatory Authorities of the European Union and the European Commission considered the essential role for WHO International Standards to be within the category of "higher order" under the European legislation. The criteria given by the ISO International Standard 17511, section 5.5 provide guidance for establishing international reference materials for biological products. This guidance list the critical parameters as traceability, uncertainty and commutability for IS value measurements [7] .
2.2 Uncertainty of biological reference materials Different features, which regarding uncertainty took on more or less importance depending on the biological substance, have being hot studied. The various components of uncertainty should be considered depending on the biological substance or the methods used to measure it and depending on whether the unit is maintained from the current reference standard to the new one. For example, uncertainty values are successful--ly used with standards of small molecule analytics that have clear defined chemical characteristics and can be assessed with a single reference methodology. The situa--tion becomes more complicated when the measured is heterogeneous and large. HBsAg is both a large particle and heter--ogeneous. Precision of measurements has the constraints of the inherent biological variability from both the measured and the test procedures.
In order to ensure the continuity of the International Standards, the uncertainties related to the measurements applied for comparison between the previous and the new standard must be carefully monitored during the establishment. In this case，the international units (IU) as the first biologi--cal reference material, is developed by WHO standard and assigned an arbitrary unitage. Such a unitage is traceable to a defined part of the content of an ampoule or vial, not possibly or not appropriately using in situations where physico-chemical determination of SI units, e.g. mass. The replacement standard will be study when the current stocks are depleted eventually. A multi-centre collaborative study will be carried out, in the beginning, to select the candidate replacement and to compare it with current IS by using multiple methods [7] .
Examples of the reference materials in infection field

The 2 nd WHO International Standard
(IS) and the Reference Panel for HBsAg [7] WHO has provided kinds of infection connected IS for market. In this paper, we only choose HBsAg International Standard (see 
